Gilead Sciences Receives Subpoena from U.S. Department of Justice
June 10 2011 - 5:07PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has
received a subpoena from the United States Attorney’s Office for
the Northern District of California requesting documents related to
the manufacture, and related quality and distribution practices, of
Atripla®, Emtriva®, Hepsera®, Letairis®, Truvada®, Viread® and our
investigational fixed-dose combination of Truvada and EdurantTM.
Gilead is cooperating in this civil and criminal investigation.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
Emtriva, Hepsera, Letairis, Truvada and Viread
are registered trademarks of Gilead Sciences, Inc.Atripla is a
registered trademark of Bristol-Myers Squibb & Gilead Sciences,
LLC.Edurant is a trademark of Tibotec Pharmaceuticals.
For more information on Gilead Sciences, please
visit the company's website at www.gilead.com or call Gilead Public
Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024